newsfilter
← Latest News
Business Wire·

GeneDx Reports Third Quarter 2026 Financial Results

WGS
  • GeneDx reported third quarter 2026 revenue of $123.1 million, including $110.4 million in exome and genome revenue.
  • Exome and genome test volume grew 25% year-over-year to 32,134 tests, with accession growth of 28%.
  • Adjusted gross margin expanded to 72% and adjusted net income reached $8.6 million for the quarter.
  • The company reiterated its full year 2026 revenue guidance of $475 million to $490 million.
  • GeneDx announced enhancements to its genome testing portfolio using long-read whole genome sequencing (lrWGS).
  • New online offerings were launched to expand access to exome testing for pediatric patients with global developmental delay, intellectual disability, or epilepsy.
  • Sponsored testing programs were introduced in collaboration with Mirum Pharmaceuticals for cholestasis and Zellweger spectrum disorder patients.
  • A partnership with Beren Therapeutics launched a sponsored program for comprehensive genome sequencing in patients with Niemann-Pick Disease Type C.
  • Medicaid coverage for whole genome sequencing was expanded to 25 states with the addition of Arkansas and Utah.
  • Nicole Maassen, J.D. was appointed as Chief Patient Access Officer to lead market access and government affairs.
  • New data demonstrated that rapid genome sequencing improves diagnostic rates and operational efficiency in pediatric inpatient care units.
  • The company presented 27 scientific abstracts at the ASHG 2026 Annual Meeting covering AI integration, standard of care advancements, and gene discovery.
  • Progress was reported on the GUARDIAN study and the BRIDGES-NBS initiative to make genomic newborn screening scalable.
  • GAAP net loss for the quarter was $12.3 million, while cash, cash equivalents, marketable securities, and restricted cash totaled $171.1 million.
  • GeneDx hosted a conference call on November 9, 2026, at 4:30 p.m. ET to discuss results.